Category: St. Jude MedicalSyndicate content

Medtech trends: The most talked about device makers in March 2014

April 2, 2014 by Arezu Sarvestani

MassDevice.com looks at the internet chatter surrounding the medical device industry with some of most searched-for companies of the last month.

chart

Click to enlarge.

MassDevice.com looked at some of the most talked-about medical device companies, based on trends in U.S. Google searches for the last 30 days.

ACC 2014 UPDATE: Reaction to Medtronic's Symplicity renal denervation data

March 31, 2014 by Brad Perriello

Medtronic's Symplicity renal denervation device for hypertension lowered blood pressure only slightly more than patients treated with drugs and a sham procedure, the company said Saturday at the American College of Cardiology's annual conference.

ACC 2014 UPDATE: Reaction to Medtronic's Symplicity renal denervation data

Medtronic (NYSE:MDT) revealed the details of a clinical trial of its Symplicity renal denervation treatment for hypertension, but said it still plans to investigate the treatment even though the study showed only meager improvements in high blood pressure compared with a sham procedure.

St. Jude's Nanostim pacemaker looks good at 3 months in feasibility study

March 25, 2014 by Brad Perriello

A small European feasibility study of the Nanostim leadless pacemaker acquired by St. Jude Medical looks good at 3 months, according to a study published in the American Heart Assn. journal Circulation.

St. Jude's Nanostim pacemaker looks good at 3 months in feasibility study

The Nanostim leadless pacemaker acquired by St. Jude Medical (NYSE:STJ) last year appeared safe and functional after 3 months, according to results of a small study published in the American Heart Assn. journal Circulation.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

AIM: Medtronic, St. Jude recalls illustrate why PMA modifications don't work

March 24, 2014 by Arezu Sarvestani

A new editorial in the Annals of Internal Medicine criticizes the premarket approval modification process, through which both Medtronic and St. Jude Medical released high-risk products that were later recalled.

AIM: Medtronic, St. Jude recalls illustrate why PMA modifications don't work

St. Jude Medical's Allure Quadra pacemaker wins FDA OK

March 24, 2014 by Brad Perriello

The FDA grants pre-market approval to St. Jude Medical's Allure Quadra cardiac resynchronization therapy pacemaker.

St. Jude Medical's Allure Quadra pacemaker wins FDA OK

St. Jude Medical (NYSE:STJ) said its Allure Quadra pacemaker will be the 1st on the U.S. market to offer quadripolar cardiac resynchronization therapy after the FDA granted pre-market approval to the device.

Get the complete picture with a MassDevice Plus membership. Registered users can login here.

Built on an AdaptiveTheme using Drupal by Michael Knapp  mknapp